Neil Gross, MD, on Emerging Treatment Spectrum in Advanced Cutaneous Squamous Cell Cancer

Posted: Friday, February 2, 2024

Neil Gross, MD, of the MD Anderson Cancer Center, Houston, discusses the use of the monoclonal antibody cemiplimab-rwlc for cutaneous squamous cell cancer, the hopes for the phase III trial of neoadjuvant cemiplimab-rwlc plus surgery, and the emerging roles of both topical therapies and immunotherapies for advanced skin cancer.

---